MIMEDX GROUP INC (MDXG) Fundamental Analysis & Valuation
NASDAQ:MDXG • US6024961012
Current stock price
3.92 USD
-0.03 (-0.76%)
At close:
3.92 USD
0 (0%)
After Hours:
This MDXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDXG Profitability Analysis
1.1 Basic Checks
- In the past year MDXG was profitable.
- In the past year MDXG had a positive cash flow from operations.
- In multiple years MDXG reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
- MDXG's Return On Assets of 14.18% is amongst the best of the industry. MDXG outperforms 94.58% of its industry peers.
- The Return On Equity of MDXG (18.94%) is better than 95.16% of its industry peers.
- The Return On Invested Capital of MDXG (16.82%) is better than 96.52% of its industry peers.
- MDXG had an Average Return On Invested Capital over the past 3 years of 16.63%. This is significantly below the industry average of 27.63%.
- The 3 year average ROIC (16.63%) for MDXG is below the current ROIC(16.82%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.18% | ||
| ROE | 18.94% | ||
| ROIC | 16.82% |
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
1.3 Margins
- MDXG has a better Profit Margin (11.60%) than 91.49% of its industry peers.
- The Operating Margin of MDXG (15.26%) is better than 92.26% of its industry peers.
- MDXG's Operating Margin has improved in the last couple of years.
- MDXG's Gross Margin of 82.56% is amongst the best of the industry. MDXG outperforms 85.69% of its industry peers.
- In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.26% | ||
| PM (TTM) | 11.6% | ||
| GM | 82.56% |
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
2. MDXG Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MDXG is creating value.
- MDXG has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for MDXG has been increased compared to 5 years ago.
- Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
- MDXG has an Altman-Z score of 6.47. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
- MDXG's Altman-Z score of 6.47 is fine compared to the rest of the industry. MDXG outperforms 76.40% of its industry peers.
- MDXG has a debt to FCF ratio of 0.25. This is a very positive value and a sign of high solvency as it would only need 0.25 years to pay back of all of its debts.
- MDXG's Debt to FCF ratio of 0.25 is amongst the best of the industry. MDXG outperforms 95.74% of its industry peers.
- MDXG has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
- MDXG has a Debt to Equity ratio of 0.06. This is comparable to the rest of the industry: MDXG outperforms 40.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.25 | ||
| Altman-Z | 6.47 |
ROIC/WACC1.82
WACC9.22%
2.3 Liquidity
- A Current Ratio of 4.32 indicates that MDXG has no problem at all paying its short term obligations.
- With a Current ratio value of 4.32, MDXG perfoms like the industry average, outperforming 49.71% of the companies in the same industry.
- MDXG has a Quick Ratio of 3.92. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of MDXG (3.92) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.32 | ||
| Quick Ratio | 3.92 |
3. MDXG Growth Analysis
3.1 Past
- MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.38%, which is quite impressive.
- The Revenue has grown by 19.99% in the past year. This is quite good.
- Measured over the past years, MDXG shows a quite strong growth in Revenue. The Revenue has been growing by 11.02% on average per year.
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
3.2 Future
- The Earnings Per Share is expected to grow by 1.82% on average over the next years.
- MDXG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.92% yearly.
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. MDXG Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.56, the valuation of MDXG can be described as reasonable.
- Compared to the rest of the industry, the Price/Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 96.91% of the companies listed in the same industry.
- MDXG's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.17.
- A Price/Forward Earnings ratio of 33.91 indicates a quite expensive valuation of MDXG.
- Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 91.30% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.05, MDXG is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.56 | ||
| Fwd PE | 33.91 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 98.07% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 98.26% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.98 | ||
| EV/EBITDA | 5.51 |
4.3 Compensation for Growth
- The decent profitability rating of MDXG may justify a higher PE ratio.
- A cheap valuation may be justified as MDXG's earnings are expected to decrease with -7.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
5. MDXG Dividend Analysis
5.1 Amount
- No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDXG Fundamentals: All Metrics, Ratios and Statistics
3.92
-0.03 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)04-28 2026-04-28
Inst Owners73.14%
Inst Owner Change0%
Ins Owners1.74%
Ins Owner Change1.43%
Market Cap582.39M
Revenue(TTM)418.63M
Net Income(TTM)48.58M
Analysts81.67
Price Target9.86 (151.53%)
Short Float %4.26%
Short Ratio6.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.4%
Min EPS beat(2)16.71%
Max EPS beat(2)110.08%
EPS beat(4)4
Avg EPS beat(4)53.83%
Min EPS beat(4)6.95%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)37.48%
EPS beat(12)11
Avg EPS beat(12)67.57%
EPS beat(16)12
Avg EPS beat(16)46.59%
Revenue beat(2)2
Avg Revenue beat(2)13.43%
Min Revenue beat(2)8.43%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)8.47%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)4.52%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)3.74%
PT rev (1m)0%
PT rev (3m)-20.76%
EPS NQ rev (1m)12.71%
EPS NQ rev (3m)-180%
EPS NY rev (1m)0%
EPS NY rev (3m)-53.74%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)-27.28%
Revenue NY rev (1m)-0.68%
Revenue NY rev (3m)-17.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.56 | ||
| Fwd PE | 33.91 | ||
| P/S | 1.39 | ||
| P/FCF | 7.98 | ||
| P/OCF | 7.87 | ||
| P/B | 2.27 | ||
| P/tB | 2.61 | ||
| EV/EBITDA | 5.51 |
EPS(TTM)0.41
EY10.46%
EPS(NY)0.12
Fwd EY2.95%
FCF(TTM)0.49
FCFY12.53%
OCF(TTM)0.5
OCFY12.71%
SpS2.82
BVpS1.73
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.18% | ||
| ROE | 18.94% | ||
| ROCE | 22.95% | ||
| ROIC | 16.82% | ||
| ROICexc | 41.72% | ||
| ROICexgc | 59.54% | ||
| OM | 15.26% | ||
| PM (TTM) | 11.6% | ||
| GM | 82.56% | ||
| FCFM | 17.43% |
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
ROICexc(3y)34.07%
ROICexc(5y)N/A
ROICexgc(3y)46.74%
ROICexgc(5y)N/A
ROCE(3y)22.68%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.46%
ROICexc growth 3YN/A
ROICexc growth 5Y12.11%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.25 | ||
| Debt/EBITDA | 0.21 | ||
| Cap/Depr | 6.94% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 51.27 | ||
| Cash Conversion | 93.95% | ||
| Profit Quality | 150.21% | ||
| Current Ratio | 4.32 | ||
| Quick Ratio | 3.92 | ||
| Altman-Z | 6.47 |
F-Score5
WACC9.22%
ROIC/WACC1.82
Cap/Depr(3y)32.56%
Cap/Depr(5y)46.17%
Cap/Sales(3y)0.47%
Cap/Sales(5y)0.75%
Profit Quality(3y)118.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
EBIT growth 1Y26.23%
EBIT growth 3YN/A
EBIT growth 5Y33.44%
EBIT Next Year-18.28%
EBIT Next 3Y13.89%
EBIT Next 5Y12.12%
FCF growth 1Y13.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.79%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
Can you provide the valuation status for MIMEDX GROUP INC?
ChartMill assigns a valuation rating of 6 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Fairly Valued.
How profitable is MIMEDX GROUP INC (MDXG) stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 7 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 9.56 and the Price/Book (PB) ratio is 2.27.
Can you provide the expected EPS growth for MDXG stock?
The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to decline by -71.81% in the next year.